Madison, WI (August 18, 2010) Quincy Bioscience announces the launch of the Quincy Animal Health division. Based on the success of the company’s patented jellyfish protein apoaequorin in human trials, Quincy Bioscience has begun product development for canine cognitive health.
Mark Underwood the company’s president explains the expansion into animal health was a logical step for Quincy Bioscience, “The essential biochemical properties of the canine brain are not very different from the human brain. Dogs are susceptible to many of the same neurological issues due to aging, such as cognitive dysfunction, we face as humans. The jellyfish protein will help dogs with healthy brain aging in the same way it helps people – by supporting calcium regulation in neurons.”
The timing of the launch coincides with the rapid growth of treatment for aging dogs. Better primary medical care for pets has lead to longer-lived dogs and subsequent increasing prevalence of canine cognitive dysfunction (CCD) which was recently estimated to be 14.2 percent of older dogs in a recent study published in The Veterinary Journal.
In addition, the animal health marketplace shows little signs of slow-down despite the recession of the past few years. Total U.S. Pet expenditures were $45.5 billion in 2009, a 5.3% increase over 2008. Projections for 2010 are $47.7 billion according to the American Pet Products Association.
David Merrick has been appointed to General Manger of Quincy Animal Health. Mr. Merrick comes from a long family history of veterinarians and an extensive background in the animal health industry including Vice President of Sales and Marketing for an animal health generic pharmaceutical company and the North American, National Sales Manager for a Swiss-based manufacturer.
“I’m extremely excited to be part of something this ground breaking for the animal health industry. The United States has 56 million senior dogs and cats with few products that effectively address the symptoms of canine cognitive dysfunction,” explained Merrick.
About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company’s products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.
